Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

3-D Tractography FUS Ablation for Essential Tremor

A legfontosabb adatok

Hol
Chapel Hill (Egyesült Államok)A helyszín megnézése

Helyszínek itt: Egyesült Államok

  • University of North Carolina at Chapel HillChapel Hill, Egyesült ÁllamokContact: Victoria ScottRésztvevőt keres

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

A vizsgálat adatai

Ki végzi
University of North Carolina, Chapel Hill
Azonosító
NCT06331052
A regiszteradat frissítve
2026. szeptember 8.
Eredeti leírás
The investigators propose to advance Vim-FUSA (Ventral Intermediate Nucleus - Focused Ultrasound Ablation) with the support of 3-D tractography, a neuroimaging technique to visually represent nerve tracts within the brain. The investigators hypothesize that 3-D tractography Vim-FUSA will improve the Vim ablation compared to standard Vim-FUSA and prove safe and feasible in the clinical setting. The investigators also hypothesize that intraoperative magnetic resonance (i-MR) monitoring will differentiate ablated tissue from immediate perilesional edema and accurately predict the Vim-FUSA clinical outcomes.A teljes eredeti leírásKevesebb

3-D Tractography Focused Ultrasound Ablation for Essential Tremor

The investigators propose to advance Vim-FUSA (Ventral Intermediate Nucleus - Focused Ultrasound Ablation) with the support of 3-D tractography, a neuroimaging technique to visually represent nerve tracts within the brain. The investigators hypothesize that 3-D tractography Vim-FUSA will improve the Vim ablation compared to standard Vim-FUSA and prove safe and feasible in the clinical setting. The investigators also hypothesize that intraoperative magnetic resonance (i-MR) monitoring will differentiate ablated tissue from immediate perilesional edema and accurately predict the Vim-FUSA clinical outcomes.

Bevonási feltételek: Diagnosis of moderate to severe ET agreed upon by at least two movement disorder trained physicians; Symptoms refractory to at least two medications; Stable essential tremor medication regimen for at least 4 weeks prior to screening; Willing and able to participate in all follow-up visits; Willing and able to undergo MR imaging.

Kizáró feltételek: Coagulopathy with inability to temporarily stop any antithrombotic medication; Unwilling or unable to undergo tremor surgery while awake; Prior brain surgery that could influence the focused ultrasound procedure outcomes, including deep brain stimulation; Botulinum toxin injection in the tremor-impacted areas three months prior to the baseline assessment and until 3-months after Vim-FUSA; Uncontrolled hypertension; Medically unstable coronary artery disease; Tremor disorders other than ET (e.g., Parkinson disease, traumatic tremor, alcohol or drug dependent tremor that remains after at least 2 weeks of abstinence etc.); Dementia; History of psychosis; Significant and non-correctible motion artifact in imaging; Pregnant at the time of enrollment or preoperative evaluation; does not qualify for FDA-approved clinical use based on current FDA labeling except that skull density ratio ≤ 0.4 will be allowed for this study; Any significant issue raised by the neurologist or neurosurgeon that may compromise participant safety or potentially interfere with study interpretation; non-English speaking.

ClinicalTrials.gov NCT06331052